Unicycive Therapeutics, Inc. (UNCY)

NASDAQ: UNCY · Real-Time Price · USD

4.100

-3.600 (-46.75%)

Jun 30, 2026, 9:31 AM EDT - Market open

-46.75% (1D)

Market Cap	109.47M +42.3%
Revenue (ttm)	n/a
Net Income	-39.89M
EPS	-2.11
Shares Out	26.70M
PE Ratio	n/a
Forward PE	1.97
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,276,707
Open	4.000
Previous Close	7.700
Day's Range	3.990 - 4.100
52-Week Range	3.710 - 8.740
Beta	1.73
Analysts	Strong Buy
Price Target	41.30 (+907.32%)
Earnings Date	Aug 13, 2026

About UNCY

Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney inj... [Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Jul 13, 2021

Employees 22

Stock Exchange NASDAQ

Ticker Symbol UNCY

Website https://unicycive.com

Full Company Profile

Financial Performance

Financial Statements

Analyst Summary

According to 10 analysts, the average rating for UNCY stock is "Strong Buy." The 12-month stock price target is $41.3, which is an increase of 907.32% from the latest price.

Price Target

$41.3

(907.32% upside)

Analyst Consensus: Strong Buy

Stock Forecasts

News

Unicycive Therapeutics receives complete response letter from FDA for OLC NDA

Unicycive Therapeutics (UNCY) announced that it has received a complete response letter, or CRL, from the FDA regarding the resubmitted new drug application, or NDA, for oxylanthanum carbonate, or OLC...

2 hours ago - TheFly

Unicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA)

-- Complete Response Letter relates to deficiencies previously identified at third-party manufacturing vendor -- -- FDA inspection of third-party facility did not occur during the NDA resubmission rev...

2 hours ago - GlobeNewsWire

Unicycive Therapeutics Proxy statement: Proxy filing

Unicycive Therapeutics filed a proxy statement on June 22, 2026, providing details for shareholder voting and corporate governance matters.

8 days ago - Filings

Unicycive Therapeutics files $150M mixed securities shelf

16:18 EDT Unicycive Therapeutics (UNCY) files $150M mixed securities shelf

24 days ago - TheFly

Unicycive Therapeutics Registration statement: Registration filing

Unicycive Therapeutics filed a registration statement on June 5, 2026, providing details about a securities offering with the SEC.

25 days ago - Filings

Unicycive Therapeutics Slides: Corporate presentation

Unicycive Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 4, 2026.

26 days ago - Filings

Unicycive Therapeutics price target raised to $18 from $15 at Benchmark

Benchmark raised the firm’s price target on Unicycive Therapeutics (UNCY) to $18 from $15 and keeps a Speculative Buy rating on the shares. The firm updated assumptions, but notes that…

4 weeks ago - TheFly